The Telix Pharmaceuticals Ltd (ASX: TLX) share price has caught the eye of investors on Thursday.
In morning trade, the radiopharmaceuticals company's shares surged over 6% to a record high of $19.06.
Telix's shares have since pulled back but remain up slightly at the time of writing.
Image source: Getty Images
Why did the Telix Pharmaceuticals share price jump to a record high?
Investors were buying the company's shares this morning after it announced that it was following in the footsteps of Life360 Inc (ASX: 360) by launching an initial public offering (IPO) on Wall Street.
According to the release, Telix Pharmaceuticals will be listing American Depositary Shares (ADSs) on the Nasdaq Global Market, each representing one ordinary share in Telix. The target size of the offering is US$200 million in gross proceeds.
In addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs sold in the offering at the initial public offering price, less underwriting discounts and commissions.
Why is Telix joining the Nasdaq?
Telix Pharmaceuticals' chair, Kevin McCann, spoke a little about the company's proposed Nasdaq listing at its annual general meeting last month.
While he wasn't able to say too much at the time, McCann stated his belief that the move would be a good one for Telix and open the door to a number of opportunities and create long term value for shareholders. McCann stated:
Last Friday, 17 May 2024, we announced the public filing of our registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) and confirmation of our intention to list on the Nasdaq Global Market. We are restricted by U.S. legal requirements on what we can say in respect of the potential U.S. listing at this stage.
But I can express our belief that this potential next step is fitting as we enter the next stage of our evolution. It enables Telix to better access the deep pool of specialist investors focused on biotechnology and radiopharmaceuticals in the U.S.
It is also our expectation that it will further increase recognition of the value of our therapeutic pipeline and raise visibility of Telix in the U.S. – and indeed globally. In turn, this will drive long-term value creation for shareholders.
The Telix Pharmaceuticals share price is now up 63% since this time last year and an even more impressive 1,600% over the last five years.
